Krystal Biotech (KRYS) Stock Looks Fully Valued on Future Earnings Hopes

Krystal Biotech stock has delivered very strong multi year returns, yet current valuation checks suggest the shares now trade on the expensive side rather than as a clear bargain. For investors trying to make sense of that gap, the recent performance history sits alongside a low overall value score and an overvalued read on market multiples.

• Over the past 5 years, Krystal Biotech has returned a very large multiple on the initial investment, which puts extra focus on whether expectations in the price have moved ahead of fundamentals.
• The key support for the current valuation is the market’s expectation that Krystal Biotech can turn its pipeline and products into durable cash flows. The main risk is that execution or regulatory setbacks slow that cash flow ramp and leave the valuation exposed.
• On a broad set of valuation checks, Krystal Biotech leans expensive rather than cheap, with 2 of 6 tests suggesting value and the overall multiple profile screening as overvalued.

The issue now is whether the current share price for Krystal Biotech still leaves enough potential upside to justify that richer valuation profile over the coming years.

Compare Krystal Biotech's premium price tag with other strong operators by scanning a hand picked list of solid balance sheet and fundamentals stocks screener (53 results) that may offer clearer value.

Is Krystal Biotech Getting Expensive on Earnings?

P/E is a useful lens for Krystal Biotech because the company is already generating earnings, so the current share price can be compared directly with those profits. On this measure, Krystal Biotech trades on a P/E of about 43.9x, which is meaningfully higher than the Biotechs industry average of roughly 17.0x and above the peer group average of about 36.1x.

The fair P/E ratio implied by the model for Krystal Biotech is around 34.2x. That is still above the broad industry, yet it sits below where the stock is currently priced. The gap suggests investors are paying a premium to what the company specific profile would indicate, even after considering its sector, scale and risk characteristics.

On the P/E multiple, Krystal Biotech stock currently screens as overvalued relative to both its peers and the modelled fair ratio.

See what the numbers say about this price — find out in our valuation breakdown.

The Krystal Biotech Narrative: What Would Justify Today's Price?

Krystal Biotech's valuation puzzle introduces the role of Simply Wall St Narratives, which explain what would need to happen to future growth, margins and earnings for the stock to trade meaningfully higher or lower than today. Each narrative links its number to a clear view on how Krystal Biotech's growth, profitability and risks could evolve, giving you something specific to return to as new information appears on the Community page.

Community narratives on Krystal Biotech are far apart, with one side focused on global expansion and the other on execution and pricing risks.

Bull case: 7% undervalued

"The expansion of Krystal's pipeline, including imminent and near-term clinical readouts in lung disease (AATD, CF), ophthalmology, oncology (NSCLC), and aesthetics, leverages increased R&D productivity, which could drive future revenue growth and diversify earnings beyond a single product…"

Read the full Bull Case to see why Krystal Biotech could be undervalued

Bear case: 26% overvalued

"Reliance on Vyjuvek faces challenges from unpredictable patient treatment patterns, pricing pressures, and reimbursement risks, impacting both revenue visibility and long-term margin stability…"

Read the full Bear Case to see why Krystal Biotech could be overvalued

Do you think there's more to the story for Krystal Biotech? Head over to our Community to see what others are saying!

The Bottom Line

For Krystal Biotech, the market multiple view points to a stock that currently screens as overvalued rather than clearly cheap. The key judgment from here is whether the current P/E premium is justified by the pace and durability of future cash flows from its products and pipeline. If execution, pricing and regulatory outcomes track toward the more optimistic narrative, today’s valuation could prove reasonable. If those expectations soften, the premium multiple may work against you, so the core question is how confident you are that Krystal Biotech can turn its current portfolio into steady, long term earnings power.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com